Transferrin saturation ratio: a method to estimate risk of cardiovascular mortality in the general population?

2014 ◽  
Vol 8 (7) ◽  
pp. 913-915 ◽  
Author(s):  
Austin G Stack ◽  
Waleed Mohamed ◽  
Mohamed Elsayed
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Transferrin Saturation ◽  
Saturation Ratio

scholarly journals Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population

QJM ◽  
2014 ◽  
Vol 107 (8) ◽  
pp. 623-633 ◽  
Author(s):  
A.G. Stack ◽  
A.I. Mutwali ◽  
H.T. Nguyen ◽  
C.J. Cronin ◽  
L.F. Casserly ◽  
...  
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Transferrin Saturation ◽  
Saturation Ratio

Low free T3 levels within the reference range independently predict cardiovascular mortality in the general population

2018 ◽  
Author(s):  
Joao Sergio Neves ◽  
Catarina Viegas Dias ◽  
Lia Leitao ◽  
Miguel Bigotte Vieira ◽  
Rita Magrico ◽  
...  
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Reference Range ◽  
Free T3

scholarly journals Plasma levels of apolipoprotein E, APOE genotype, and all-cause and cause-specific mortality in 105 949 individuals from a white general population cohort

2019 ◽  
Vol 40 (33) ◽  
pp. 2813-2824 ◽  
Author(s):  
Katrine L Rasmussen ◽  
Anne Tybjærg-Hansen ◽  
Børge G Nordestgaard ◽  
Ruth Frikke-Schmidt
Keyword(s):  
General Population ◽  
Cardiovascular Mortality ◽  
Cancer Mortality ◽  
Plasma Levels ◽  
Apoe Genotype ◽  
High Plasma ◽  
Increased Risk ◽  
Specific Mortality ◽  
General Population Cohort ◽  
Low Levels

Abstract Aims To determine whether plasma apoE levels and APOE genotype are associated with all-cause and cause-specific mortality. Methods and results Using a prospective cohort design with 105 949 white individuals from the general population, we tested the association between plasma apoE at study enrolment and death during follow-up, and whether this was independent of APOE genotype. We confirmed the well-known association between APOE genotypes and mortality. For all-cause, cardiovascular, and cancer mortality, high levels of apoE were associated with increased risk, while for dementia-associated mortality low levels were associated with increased risk. For the highest vs. the fifth septile of plasma apoE, hazard ratios (HRs) were 1.20 (95% confidence interval 1.12–1.28) for all-cause mortality, 1.28 (1.13–1.44) for cardiovascular mortality, and 1.18 (1.05–1.32) for cancer mortality. Conversely, for the lowest vs. the fifth septile the HR was 1.44 (1.01–2.05) for dementia-associated mortality. Results were similar in analyses restricted to APOE ɛ33 carriers. Examining genetically determined plasma apoE, a 1 mg/dL increase conferred risk ratios of 0.97 (0.92–1.03) for cardiovascular mortality and 1.01 (0.95–1.06) for cancer mortality, while a 1 mg/dL decrease conferred a risk ratio of 1.70 (1.36–2.12) for dementia-associated mortality. Conclusion High plasma levels of apoE were associated with increased all-cause, cardiovascular, and cancer mortality, however of a non-causal nature, while low levels were causally associated with increased dementia-associated mortality.

scholarly journals Iron Status in Hypogammaglobulinemia

1985 ◽  
Vol 78 (10) ◽  
pp. 838-841
Author(s):  
Hasan I Atrah
Keyword(s):  
Iron Deficiency ◽  
General Population ◽  
Intravenous Immunoglobulin ◽  
Serum Ferritin ◽  
Iron Status ◽  
Transferrin Saturation ◽  
The State ◽  
Serum Samples ◽  
Serum Igg

Iron, transferrin and ferritin were measured in serum samples from 16 patients with primary hypogammaglobulinemia. Transferrin saturation was low in 12 patients (75%) and serum ferritin was low in 9 patients (56.25%). Both parameters were low, confirming the state of iron deficiency, in 6 patients (37.5%). These figures are highly significant ( P < 0.01) when compared with the prevalence of iron deficiency in the general population. Eight patients were maintained on intravenous immunoglobulin infusions and the rest on intramuscular immunoglobulin injections, their mean serum IgG being 4.4 g/l and 2.6 g/l respectively. There was no difference in the prevalence of iron deficiency between the two groups.

Individual 6-year systolic blood pressure change and impact on cardiovascular mortality in a French general population

2015 ◽  
Vol 30 (1) ◽  
pp. 18-23 ◽  
Author(s):  
B Pannier ◽  
F Thomas ◽  
O Hanon ◽  
S Czernichow ◽  
C Lemogne ◽  
...  
Keyword(s):  
Blood Pressure ◽  
General Population ◽  
Systolic Blood Pressure ◽  
Cardiovascular Mortality ◽  
Pressure Change ◽  
Blood Pressure Change

scholarly journals Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis

2014 ◽  
Vol 99 (6) ◽  
pp. 2018-2029 ◽  
Author(s):  
Nicholas A. Tritos ◽  
Gudmundur Johannsson ◽  
Márta Korbonits ◽  
Karen K. Miller ◽  
Ulla Feldt-Rasmussen ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
General Population ◽  
Outcome Measures ◽  
Cardiovascular Mortality ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
World Health ◽  
Gh Replacement

Context: GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD). Objective: Our objective was to examine the effectiveness and safety of GH replacement in acroGHD. Design: This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database). Setting: Data were extracted from a pharmaco-epidemiological survey of &gt;16 000 GHD adults from 31 countries. Patients: The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease). Outcome Measures: Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints. Results: Median GH dose was 0.3 mg/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA (standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed/expected cases [95% confidence interval] = 1.32 [0.70–2.25]) and lower in NFPA [observed/expected = 0.58 [0.48–0.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA. Conclusions: GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD.

scholarly journals The significance of haemochromatosis gene mutations in the general population: implications for screening

Gut ◽  
1998 ◽  
Vol 43 (6) ◽  
pp. 830-836 ◽  
Author(s):  
M J Burt ◽  
P M George ◽  
J D Upton ◽  
J A Collett ◽  
C M A Frampton ◽  
...  
Keyword(s):  
General Population ◽  
Serum Iron ◽  
Deoxyribonucleic Acid ◽  
Iron Status ◽  
Transferrin Saturation ◽  
Gene Mutations ◽  
The Other ◽  
Phenotypic Screening ◽  
C282y Mutation ◽  
C282y Homozygosity

Background—Haemochromatosis is associated with mutations in the HFE gene but the significance of these mutations in the general population is unknown.Aims—To determine the frequency ofHFE gene mutations in the general population, their effect on serum iron indexes, and their role in screening for haemochromatosis.Methods—Deoxyribonucleic acid (DNA) from 1064 randomly selected subjects was analysed for the C282Y and H63D mutations in the HFE gene. Serum iron, transferrin saturation, and ferritin were measured and individuals with increased iron indexes were investigated to confirm or exclude a clinical diagnosis of haemochromatosis.Results—Mutations were identified in 409 individuals (38.4%) with heterozygote (carrier) frequencies of 13.2% and 24.3% for the C282Y and H63D mutations respectively. Heterozygosity for either mutation significantly increased serum iron and transferrin saturation but despite a similar trend for ferritin, this was only significant for C282Y homozygotes. Five individuals (0.47%) were homozygous for the C282Y mutation, three of whom had haemochromatosis confirmed by liver biopsy (0.28%). The other two C282Y homozygotes would not have been detected by phenotypic screening alone.Conclusions—HFE mutations are present in 38.4% of the population, affect serum iron indexes, and are important determinants of iron status. The population frequency of genetically defined haemochromatosis (C282Y homozygosity) is approximately one in 200 and is higher than the prevalence of clinically apparent haemochromatosis.

Sign in / Sign up

Export Citation Format

Share Document